Dr. Grunwald on Preventing Relapse in Lymphoid and Myeloid Malignancies

May 4, 2021
Michael R. Grunwald, MD, FACP

Michael R. Grunwald, MD, FACP, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.

Michael R. Grunwald, MD, FACP, a clinical assistant professor of medicine at the University of North Carolina, as well as a hematologist/oncologist at Levine Cancer Institute, Atrium Health, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.

Several ongoing efforts seek to prevent relapse in patients with myeloid and lymphoid malignancies, according to Grunwald. Many of these strategies incorporate targeted agents after transplantation. For example, in patients who have FLT3 mutations, or those with leukemia harboring a Philadelphia chromosome, a targeted inhibitor will be utilized following transplantation, Grunwald says.

However, a prospective study demonstrating an advantage for a targeted inhibitor after transplant has yet to be conducted. Currently, an ongoing study in patients with FLT3 mutations is examining the use of gilteritinib (Xospata) vs placebo after transplantation, the results of which are anticipated, Grunwald concludes.